FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Seeks Faster IND-To-Approval Timelines, Expanded OTC Access

FDA commissioner Marty Makary says the agency is prioritizing efforts to accelerate drug development timelines beginning at the IND stage, while also ...

latest-news-card-1
Human Drugs

New CBER Head Should Restore Rare Disease Clarity: Advocates

A rare disease coalition calls on the Trump administration to appoint a new CBER director who understands rare disease drug development and values the...

latest-news-card-1
Human Drugs

Lillys Oral Obesity Drug Foundayo Wins Approval

Eli Lilly wins FDA approval for Foundayo (orforglipron), a once-daily oral treatment for adults with obesity or those who are overweight with related ...

latest-news-card-1
Human Drugs

Appeals Court Hears GLP-1 Compounding Testimony

A Courthouse New Service report outlines the competing arguments made before a three-judge appeals court panel in a case involving FDAs decision to re...

latest-news-card-1
Medical Devices

Multiple Violations in Physitemp Instruments Inspection

FDA warns Clifton, NJ-based Physitemp Instruments about Quality System, Medical Device Reporting, Unapproved Device, and Unique Device Identifier viol...

latest-news-card-1
Human Drugs

FDA Extends Review Timeline for Orca Bios Cell Therapy Orca-T

FDA extends by three months its review of an Orca Bio BLA for its experimental cell therapy Orca-T, indicated for treating a range of hematologic mali...

latest-news-card-1
Biologics

Xbrane Plans Resubmission of Lucentis Biosimilar by June

Xbrane Biopharma says it plans to resubmit a BLA before June for ranibizumab, a biosimilar copy of Genentechs Lucentis, which is indicated for treatin...

latest-news-card-1
Human Drugs

Multiple Violations at LeeSar Outsourcing Facility

An FDA untitled letter cautions the Fort Myers, FL-based LeeSar drug outsourcing facility about CGMP and other violations in its production of compoun...

latest-news-card-1
Human Drugs

FDA-483 Not a Proxy for Overall Quality: Califf

Former FDA commissioner Robert Califf says form FDA-483 is a useful regulatory tool for identifying issues that companies should correct, but it shoul...

latest-news-card-1
Human Drugs

CGMP Deviations in Henan Lvyuan Inspection

FDA warns Henan, China-based Henan Lvyuan Pharmaceutical Company about significant deviations from current good manufacturing practices for active pha...